StockNews.AI
PLRX
StockNews.AI
116 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc. – PLRX

1. Pomerantz LLP investigates potential securities fraud involving Pliant Therapeutics. 2. Pliant paused enrollment in the BEACON-IPF trial for bexotegrast on February 7, 2025. 3. Wells Fargo and Citi downgraded Pliant after the drug trial was halted. 4. Pliant's share price plummeted 60.59%, closing at $3.07 per share. 5. Investors are urged to contact Pomerantz LLP for possible class action participation.

3m saved
Insight
Article

FAQ

Why Very Bearish?

The significant stock price drop after trial halt suggests severe investor loss of confidence, common in such cases.

How important is it?

The investigation could lead to further legal complications, negatively impacting PLRX's reputation and stock performance.

Why Short Term?

Immediate effects are observed due to ongoing investigations and current market sentiment volatility.

Related Companies

WFCC
NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc (“Pliant” or the “Company”) (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Pliant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 7, 2025, Pliant issued a press release “announc[ing] that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF).” Following this news, Wells Fargo and Citi analysts both downgraded Pliant, citing uncertainty about bexotegrast’s path forward. On this news, Pliant’s stock price fell $4.72 per share, or 60.59%, to close at $3.07 per share on February 10, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News